Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

121results about How to "Longer acting" patented technology

Q: How to Longer acting?

Use of angiotensin ii agonists,Amidino derivatives and their use as thrombin inhibitors,Thiochromane derivatives and their use as thrombin inhibitors,Amidino derivatives and their use as thrombin inhibitors,INHIBITOR OF p38 MAP KINASE

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Use of angiotensin ii agonists

InactiveUS20120035232A1High expressionPromoting reinnervationOrganic active ingredientsBiocideMedicineAgonist

There is provided a compound of formula I,wherein Y1, Y2, Y3, Y4, Z1, Z2, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, for use in the treatment of spinal cord injury.

View all

Owner:VICORE PHARMA AB

Amidino derivatives and their use as thrombin inhibitors

InactiveUS6221898B1More efficaciousToxic reductionBiocidePeptide/protein ingredientsAmidino derivativeThrombin activity

There is provided compounds of formula I,wherein R1, R2, R3, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Amidino derivatives and their use as thrombin inhibitors

View all

Owner:ASTRAZENECA AB

Thiochromane derivatives and their use as thrombin inhibitors

InactiveUS6716834B2Toxic reductionLonger actingOrganic active ingredientsBiocideThrombusPharmaceutical drug

There is provided compounds of formulae I and IAwherein Y, R<1>, R<2>, R<3>, D<1 >and D<2 >have meanings given in the description which are useful as, or as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Thiochromane derivatives and their use as thrombin inhibitors

View all

Owner:ASTRAZENECA AB

Amidino derivatives and their use as thrombin inhibitors

InactiveUS6265397B1More efficaciousToxic reductionBiocideOrganic chemistryThrombusAmidino derivative

There is provided compounds of formula I,wherein R1, Rx, Y, Ry, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

View all

Owner:ASTRAZENECA AB

INHIBITOR OF p38 MAP KINASE

ActiveUS20150232450A1Toxic reductionLonger actingPowder deliveryOrganic active ingredientsMedicineKinase

A compound has the following formula:The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

View all

Owner:RESPIVERT

Abuse resistant formula

ActiveUS20120015007A1Avoidance and reduction of riskGood sustained release effectBiocideNervous disorderChronic painFilm-forming agent

There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.

View all

Owner:EMPLICURE AB

Bis-aryl compounds for use as medicaments

InactiveUS20110112193A1Toxic reductionLonger actingBiocideSenses disorderArylMedicine

There is provided compounds of formula (I), wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and / or required, and particularly in the treatment of a respiratory disorder and / or inflammation.

Bis-aryl compounds for use as medicaments

View all

Owner:BIOLIPOX AB

Amidinobenzylamine derivatives and their use as thrombin inhibitors

InactiveUS6599894B1Longer actingWide range of activitiesBiocidePeptide/protein ingredientsAnticoagulantThrombin activity

There is provided compounds of formula Iwherein R1, R2, Y, R3 and R4 have meanings given in the description which are useful as, or as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Amidinobenzylamine derivatives and their use as thrombin inhibitors

View all

Owner:ASTRAZENECA AB

Amino acid derivatives and their use as thrombin inhibitors

InactiveUS6255301B1More efficaciousToxic reductionSilicon organic compoundsBiocideAnticoagulantThrombin activity

There is provided compounds of formula I,wherein R1, R2, R3, Rx, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required as in thrombosis or as anticoagulants.

Amino acid derivatives and their use as thrombin inhibitors

View all

Owner:ASTRAZENECA AB

Positive modulators of nicotinic acetylcholine receptors

InactiveUS20070179172A1More efficaciousLonger actingBiocideNervous disorderCompound (substance)Stereochemistry

Compounds of Formula I or Formula II wherein R1, X and Ar are as described in the specification, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.

Positive modulators of nicotinic acetylcholine receptors

View all

Owner:ASTRAZENECA AB

Breakthrough pain management

InactiveUS20090011030A1Treatment and alleviation of painAct quicklyBiocidePowder deliveryPulmonary inhalationFentanyl

The present invention is directed to a powdered formulation comprising an analgesic, preferably fentanyl, for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as well as effective analgesic amounts of fentanyl in a shorter time and at lower dose levels of administered fentanyl when compared to fentanyl administered by an oral transmucosal route.

View all

Owner:LAB INT

Beta Amino Acid Derivatives as Integrin Antagonists

ActiveUS20140038910A1Sufficient amountToxic reductionBiocideUrea derivatives preparationIntegrin antagonistFibrosis

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula:wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Beta Amino Acid Derivatives as Integrin Antagonists

View all

Owner:SAINT LOUIS UNIVERSITY

Controlled release pharmaceutical composition

InactiveUS20130171199A1Reduce dosing frequencyLonger actingBiocideDispersion deliveryControlled releaseExcipient

An oral controlled release pharmaceutical composition comprising a core and a polymer dispersion and its preparation method are disclosed. The core is selected from the group consisting of ‘the drug coated core’ and ‘the drug loaded core’. The drug coated core comprises an inert excipient based sphere and a coat of drug composition. The drug loaded core comprises at least a drug, a binder and at least one pharmaceutically acceptable excipient. The polymer dispersion used to coat the core comprises at least one controlled release polymer and at least one pharmaceutically acceptable excipient. The oral controlled release pharmaceutical composition further comprises an in-situ gelling system comprising at least one gelling polymer.

View all

Owner:ABBOTT HEALHCARE PROD BV

Imidazopyridazines for Use as Protein Kinase Inhibitors

InactiveUS20110046127A1Easy to convertToxic reductionBiocideOrganic chemistryPTK InhibitorsIsrapafant

There is provided compounds of formula (I): wherein Z, M, R1, X, R3, R4 and R5 have meanings given in the description, an pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PIM family kinase or PI3-K) is desired and / or required, an particularly in the treatment of cancer.

Imidazopyridazines for Use as Protein Kinase Inhibitors

View all

Owner:FUNDACION CENT NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

New compounds

InactiveUS20100256188A1More efficaciousToxic reductionBiocideNervous disorderMedicine

The present invention relates to compounds of general formula Iin which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof.The compounds are of potential utility in the treatment and / or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and / or prevention of pain.The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

View all

Owner:BOEHRINGER INGELHEIM INT GMBH

Inhibitor of p38 map kinase

ActiveUS9447076B2Toxic reductionLonger actingOrganic active ingredientsPowder deliveryMedicineKinase

View all

Owner:RESPIVERT

Bis-aromatic compounds useful in the treatment of inflammation

InactiveUS20100286215A1More efficaciousToxic reductionBiocideSenses disorderDiseaseMedicine

There is provided compounds of formula (I): wherein Y, ring A, D1, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and / or required, and particularly in the treatment of a respiratory disorder and / or inflammation.

Bis-aromatic compounds useful in the treatment of inflammation

View all

Owner:BIOLIPOX AB

1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents

InactiveUS20110312935A1Reduce formationMore efficaciousBiocideSenses disorderDiseasePharmaceutical medicine

There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and / or required, and particularly in the treatment of inflammation and / or cancer.

1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents

View all

Owner:OREXO AB

Transdermal drug administration device

ActiveUS20130273119A1Prevent extractionLonger actingBiocideNervous disorderDrug administrationCarrier material

A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

View all

Owner:EMPLICURE AB

New compounds

InactiveUS20120196897A1Toxic reductionLonger actingBiocideNervous disorderMedicine

View all

Owner:BOEHRINGER INGELHEIM INT GMBH

Bis-aryl compounds for use as medicaments

InactiveUS20110071197A1More efficaciousToxic reductionBiocideSenses disorderArylMedicine

There is provided compounds of formula I, wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and / or required, and particularly in the treatment of a respiratory disorder and / or inflammation.

View all

Owner:BIOLIPOX AB

Pyrazoles Useful in the Treatment of Inflammation

InactiveUS20090143455A1Improve oral bioavailabilityReduce gapBiocideOrganic active ingredientsDiseaseLipoxygenase activity

There is provided compounds of formula I,wherein R1, R2, X1, X2 and n have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and / or required, and particularly in the treatment of inflammation.

Pyrazoles Useful in the Treatment of Inflammation

View all

Owner:BIOLIPOX AB

N-myristoyl transferase inhibitors

ActiveUS9156811B2Improve permeabilityRapid onset of activityBiocideAntimycoticsN-myristoyltransferaseBiochemistry

The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.

View all

Owner:UNIVERSITY OF DUNDEE

Water Injection Device for an Internal Combustion Engine of a Motor Vehicle

InactiveUS20190257270A1Little biocontaminationLonger actingInternal combustion piston enginesNon-fuel substance addition to fuelExternal combustion engineInternal combustion engine

A water injection device for an internal combustion engine of a motor vehicle includes at least one water injector for injecting water into an internal combustion engine. The water injection device further includes a water tank and a first supply line. The first supply line is configured to connect the water tank to the water injector. At least one biocide for controlling harmful organisms in the water injection device is provided in the water injection device.

View all

Owner:ROBERT BOSCH GMBH

Bis Aromatic Compounds for Use in the Treatment of Inflammation

InactiveUS20110294853A1Toxic reductionLonger actingBiocideOrganic chemistryMedicineLeukotriene C4

There is provided compounds of formula (I), wherein ring A, D1, D2a, D2b, D3, Y, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and / or required, and particularly in the treatment of a respiratory disorder and / or inflammation.

Bis Aromatic Compounds for Use in the Treatment of Inflammation

View all

Owner:BIOLIPOX AB

Composition for sustained drug delivery comprising geopolymeric binder

ActiveUS20120252845A1Low risk of and diversionSustained releaseBiocideNervous disorderDrug deliveryGeopolymer

The present invention relates to a sustained release medical composition comprising an active pharmaceutical ingredient and a geopolymeric binder. Preferably the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder.

Composition for sustained drug delivery comprising geopolymeric binder

View all

Owner:EMPLICURE AB

Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

ActiveUS20140275493A1Extended half-lifeReduce the burden onImmunoglobulins against animals/humansFermentationAntigenLow affinity

Antibodies are disclosed that bind to and inhibit the anti-coagulant function of TFPI and have a lower affinity for TFPI at pH 6.0 than at pH 7.4. The lower affinity at pH 6 improves circulating half-life (T½) due to reduced target mediated clearance, a process by which an antibody / antigen complex is endocytosed and trafficked to the lysosome where both components are degraded. The lower affinity at pH 6.0 results in disruption of the complex prior to lysosome targeting and allows for re-circulation of the antibody. Specific modifications to antibody binding by histidine residue substitution are disclosed along with methods of use.

Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics

View all

Owner:BAYER HEALTHCARE LLC

Positive modulators of nicotinic receptor agonists

InactiveUS20050245595A1Enhance efficacy of agonistRestore normal interneuronal communicationBiocideNervous disorderEnantiomerNicotinic Receptor Agonist

Compounds according to formula I: wherein R1, W, R2, R3, X, R4 and R5 are as described in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.

Positive modulators of nicotinic receptor agonists

View all

Owner:ASTRAZENECA AB

Selective etching of a matrix comprising silver NANO wires

InactiveUS20140291287A1Improve throughputLess expensiveDecorative surface effectsSolid-state devicesEtchingCarbon nanotube

The present invention refers to a method for selectively structuring of a polymer matrix comprising AgNW (silver nano wires) or CNTs (carbon nano tubes) or comprising mixtures of AgNW and CNTs on a flexible plastic substructure or solid glass sheet. The method also includes a suitable etching composition, which allows to proceed the method in a mass production.

Selective etching of a matrix comprising silver NANO wires

View all

Owner:MERCK PATENT GMBH

Imidazolothiadiazoles for use as protein kinase inhibitors

ActiveUS8563550B2Easy to convertMore efficaciousBiocideNervous disorderDiseasePTK Inhibitors

There is provided compounds of formula (I), wherein Z, M, R1, X, R2, R3 and B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PIM family kinase or PI3-K) is desired and / or required, and particularly in the treatment of cancer.

Imidazolothiadiazoles for use as protein kinase inhibitors

View all

Owner:FUNDACION CENT NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

121results about How to "Longer acting" patented technology

Popular searches